SCHEMBL5652837

SCHEMBL5652837

COc1cc(Nc2ncnc3cc(OC)c(OC)cc23)c(OC)cc1Cl

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.87
SRC P12931 3/20 0.87
RIPK2 O43353 1/20 0.87
NOD1 Q9Y239 1/20 0.87
KDR P35968 14/20 0.69
RET P07949 7/20 0.69
KIF5B P33176 5/20 0.69
EPHB4 P54760 3/20 0.66
EPHA2 P29317 3/20 0.66
FLT1 P17948 3/20 0.64
FLT4 P35916 2/20 0.64
FGFR1 P11362 1/20 0.64
EPHB2 P29323 1/20 0.64
AURKA O14965 1/20 0.60
ERBB2 P04626 1/20 0.60
INSR P06213 1/20 0.60
FBP1 P09467 1/20 0.60
PDGFRB P09619 1/20 0.60
CLK1 P49759 1/20 0.60
TEK Q02763 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649893 0.84 EGFR (0.64) EGFRSRCRIPK2NOD1KDR
SCHEMBL7116324 0.84 SRC (0.75) EGFRSRCRIPK2NOD1KDR
SCHEMBL5649023 0.83 EGFR (0.62) EGFRSRCRIPK2NOD1KDR
SCHEMBL5649183 0.83 EGFR (0.62) EGFRSRCRIPK2NOD1KDR
SCHEMBL5652519 0.83 EGFR (0.72) EGFRSRCKDREPHB4EPHA2
SCHEMBL5649175 0.83 KDR (0.79) EGFRSRCRIPK2KDRRET
SCHEMBL6944605 0.83 EGFR (1.00) EGFRSRCRIPK2NOD1KDR
SCHEMBL5648329 0.83 EGFR (0.61) EGFRSRCRIPK2NOD1KDR
Hydrochloric Acid SCHEMBL28028278 0.82 EGFR (0.80) EGFRSRCRIPK2NOD1KDR
SCHEMBL5648497 0.82 EPHA2 (0.73) EGFRSRCRIPK2NOD1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299092-A1 Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors WYETH (US) 2007-12-27 US disclosed
EP-1866311-A2 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-12-19 EP disclosed
WO-2006104889-A2 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-10-05 WO disclosed
WO-2005115145-A2 QUINONE SUBSTITUTED QUINAZOLINE AND QUINOLINE KINASE INHIBITORS WYETH (US) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299092-A1 Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors KDR, FLT1, FLT4 EGFR 439/4885SRC 960/4885RIPK2 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.